NEW YORK (GenomeWeb News) – VisEn Medical today said that the Swiss Federal Institute of Technology will use its portfolio of in vivo fluorescence probes and fluorescence molecular tomography imaging system in its molecular imaging programs.
VisEn said its technologies are designed to identify, characterize, and quantify a range of biological phenomena in vivo, including known molecular activities underlying disease states such as cancer, inflammation, cardiovascular disease, and bone disease.
The technology will be used in the lab of Markus Rudin, whom the company has appointed to its scientific advisory board.
Rudin is a professor of molecular imaging and functional pharmacology at the Swiss Federal Institute of Technology and the University of Zürich. He has been the head of imaging technologies at Novartis.